EMPAGLIFLOZIN IMPROVES VASCULAR REGENERATIVE CELL CONTENT IN PEOPLE WITHOUT DIABETES
Ehab Bakbak(The University of Queensland), David A. Hess(Western University), Catharine Wang(Boston University), A. Krishnaraj(Toronto Public Health), P. Puar(Toronto Public Health), C. David Mazer(St. Michael's Hospital), Hwee Teoh(St. Michael's Hospital), Kim A. Connelly(St. Michael's Hospital), R. Verma(Toronto Public Health), Daniella C. Terenzi(St. Michael's Hospital), Tamique Mason(Toronto Public Health), Subodh Verma(St. Michael's Hospital), Ori D. Rotstein(St. Michael's Hospital), Adrian Quan(St. Michael's Hospital), Andrew T. Yan(St. Michael's Hospital)
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
New Markers of Inflammation and Endothelial Cell Activation
|Circulation|2003|733
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
|New England Journal of Medicine|2021|711
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693